MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.

Fortunato Ciardiello,Manuel Cobo-Dols,Oscar Juan Vidal,Luis Paz-Ares,Javier de Castro-Carpeño,Enriqueta Felip,Rosario García-Campelo,György Losonczy,Zsuzsanna Szalai,D. Vicente,Andreas Schröder,Frank Beier,Prasad Bhandge,Gabriella Gálffy

MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.

2019

Fortunato Ciardiello
Manuel Cobo-Dols
Oscar Juan Vidal
Luis Paz-Ares
Javier de Castro-Carpeño
Enriqueta Felip
Rosario García-Campelo
György Losonczy
Zsuzsanna Szalai
D. Vicente
Andreas Schröder
Frank Beier
Prasad Bhandge
Gabriella Gálffy

TPS9123Background: Preclinical studies have demonstrated that cetuximab plus chemotherapy results in immunogenic cell death and an increase in CD8+ T cells in the tumor microenvironment. Avelumab (...

Keywords:

Tumor microenvironment
Avelumab
Cancer research
Cetuximab
CD8
Gemcitabine
Cisplatin
Pathology
Immunogenic cell death
Chemotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations